{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:12:06Z","timestamp":1789139526467,"version":"build-2803163510"},"reference-count":96,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: MEK inhibitors (selumetinib, mirdametinib) are the only approved class of targeted therapy for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN), producing partial responses in a substantial proportion of patients (up to 63.6% in adults; objective response rate 19.7% versus 5.4% with placebo in the KOMET trial). Responses, however, are rarely complete or durable, and in malignant peripheral nerve sheath tumor (MPNST) single-agent MEK inhibition is clinically ineffective. Mechanisms of escape from MEK inhibition in these tumors remain poorly characterized and are reported in the literature as isolated primary studies without an integrative analysis. The aim of this review was to systematize both the established molecular mechanisms of resistance to MEK inhibitors in PN and MPNST and the biologically plausible candidate mechanisms extrapolated from other RAS-driven malignancies. Methods: This is a narrative review. A structured search was performed in PubMed, PubMed Central, NCBI Bookshelf, and Scopus, supplemented by clinical practice guidelines and regulatory documents; it covered publications up to 31 May 2026 and was updated in August 2026. Ninety-six sources are cited, and their composition by publication type is reported; record counts at the intermediate screening steps were not maintained, and no PRISMA flow diagram is presented. Results: Mechanisms were classified within a convergent framework into six categories: reactivation of MAPK signaling within the cascade; parallel (bypass) reactivation through receptor tyrosine kinases and adjacent inputs; epigenetic and transcriptional rewiring; cell survival programs; the tumor microenvironment and immune evasion; and intratumoural heterogeneity. Each mechanism was then graded along two independent axes\u2014the strength of evidence that it confers resistance in PN or MPNST (E1\u2013E3) and its therapeutic tractability (T1\u2013T3)\u2014and annotated with the entity and model constituting its evidence source. Conclusions: Resistance to MEK inhibition in PN and MPNST is convergent rather than mechanism-unique. The principal limitation of the field is the near-absence of clinical resistance data from patients progressing on MEK inhibitors; prospective molecular monitoring, rational combination trials, and mechanism-stratifying biomarkers are the priorities.<\/jats:p>","DOI":"10.3390\/cancers18182950","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:39:24Z","timestamp":1789137564000},"page":"2950","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of Resistance to MEK Inhibitors (RAS\u2013MAPK Pathway) in Malignant Peripheral Nerve Sheath Tumors and Their Precursor Lesions (Plexiform Neurofibromas) Associated with Neurofibromatosis Type 1"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8420-6852","authenticated-orcid":false,"given":"Sergey I.","family":"Sologov","sequence":"first","affiliation":[{"name":"Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-7802","authenticated-orcid":false,"given":"Diana","family":"Sologova","sequence":"additional","affiliation":[{"name":"Department of Oral Surgery, Institute of Dentistry, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Dubinin","sequence":"additional","affiliation":[{"name":"Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Anikin","sequence":"additional","affiliation":[{"name":"Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Bekhorashvili","sequence":"additional","affiliation":[{"name":"Department of Regulatory Relations in the Field of Circulation of Medicines and Medical Devices, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rayisyan","sequence":"additional","affiliation":[{"name":"Department of Regulatory Relations in the Field of Circulation of Medicines and Medical Devices, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Krylova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy of Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-5786","authenticated-orcid":false,"given":"Milada","family":"Yarkova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy of Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-4396","authenticated-orcid":false,"given":"Ekaterina M.","family":"Grigorevskikh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy of Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2615-7167","authenticated-orcid":false,"given":"Elena","family":"Smolyarchuk","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy of Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-7147","authenticated-orcid":false,"given":"Susanna","family":"Sologova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy of Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis Type 1: A Multidisciplinary Approach to Care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the Pathogenesis of Malignant Tumours in Neurofibromatosis Type 1","volume":"10","author":"Brems","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_3","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Neurofibromatosis 1. GeneReviews\u00ae, University of Washington."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1038\/s41467-025-57077-1","article-title":"A Genotype-First Approach Identifies High Incidence of NF1 Pathogenic Variants with Distinct Disease Associations","volume":"16","author":"Safonov","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/neuonc\/noag023","article-title":"Neurofibromatosis Type 1-Plexiform Neurofibromas: Integrating Treatment across Pediatric and Adult Populations","volume":"28","author":"Armstrong","year":"2026","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic Evaluation of Atypical Neurofibromatous Tumors and Their Transformation into Malignant Peripheral Nerve Sheath Tumor in Patients with Neurofibromatosis 1-a Consensus Overview","volume":"67","author":"Miettinen","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2009.11.FOCUS09221","article-title":"Neurofibromatosis Type 1 and Tumorigenesis: Molecular Mechanisms and Therapeutic Implications","volume":"28","author":"Gottfried","year":"2010","journal-title":"Neurosurg. Focus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and Prevalence of Neurofibromatosis Type 1 and 2: A Systematic Review and Meta-Analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of Neurofibromatosis Type 1 in the Finnish Population","volume":"20","author":"Uusitalo","year":"2018","journal-title":"Genet. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS Tumour Surveillance Guidelines for Individuals with Neurofibromatosis Type 1","volume":"56","author":"Carton","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant Peripheral Nerve Sheath Tumours in Neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of Adults with Neurofibromatosis Type 1: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","article-title":"Malignant Peripheral Nerve Sheath Tumors. A Clinicopathologic Study of 120 Cases","volume":"57","author":"Ducatman","year":"1986","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.wneu.2017.06.010","article-title":"Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review","volume":"105","author":"Yamanaka","year":"2017","journal-title":"World Neurosurg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 Is Recurrently Inactivated through EED or SUZ12 Loss in Malignant Peripheral Nerve Sheath Tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration, and Center for Drug Evaluation and Research (2026, May 16). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in Adults with NF1 and Inoperable Plexiform Neurofibroma: A Phase 2 Trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and Safety of Selumetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multicentre, International, Randomised, Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-21-3760","article-title":"The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children with Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jid.2021.07.164","article-title":"Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK\/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I","volume":"142","author":"Wang","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/bjc.2014.139","article-title":"Mechanism and Consequences of RAF Kinase Activation by Small-Molecule Inhibitors","volume":"111","author":"Holderfield","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1158\/1078-0432.CCR-24-1750","article-title":"MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor","volume":"30","author":"Lee","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ra17","DOI":"10.1126\/scisignal.2001752","article-title":"Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1\/2 Inhibitors in Colorectal Cancer Cells","volume":"4","author":"Little","year":"2011","journal-title":"Sci. Signal."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-024-44755-9","article-title":"Functional Interactions between Neurofibromatosis Tumor Suppressors Underlie Schwann Cell Tumor De-Differentiation and Treatment Resistance","volume":"15","author":"Vasudevan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","article-title":"Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/jpet.122.001431","article-title":"Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage","volume":"385","author":"Jackson","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1535-7163.MCT-24-1053","article-title":"Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors","volume":"25","author":"Williams","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/0008-5472.CAN-20-1992","article-title":"Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2407745121","DOI":"10.1073\/pnas.2407745121","article-title":"Hydroxychloroquine Prevents Resistance and Potentiates the Antitumor Effect of SHP2 Inhibition in NF1-Associated Malignant Peripheral Nerve Sheath Tumors","volume":"122","author":"Sait","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.expneurol.2017.10.012","article-title":"Development of 3D Culture Models of Plexiform Neurofibroma and Initial Application for Phenotypic Characterization and Drug Screening","volume":"299","author":"Kraniak","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-23-0749","article-title":"CDK4\/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression","volume":"29","author":"Kohlmeyer","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109689","DOI":"10.1016\/j.cellsig.2020.109689","article-title":"Phosphorylation of the mRNA Cap-Binding Protein eIF4E and Cancer","volume":"73","author":"Yang","year":"2020","journal-title":"Cell Signal"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.celrep.2014.03.041","article-title":"Mnk2 Alternative Splicing Modulates the P38-MAPK Pathway and Impacts Ras-Induced Transformation","volume":"7","author":"Maimon","year":"2014","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.febslet.2013.06.045","article-title":"Rapamycin Enhances eIF4E Phosphorylation by Activating MAP Kinase-interacting Kinase 2a (Mnk2a)","volume":"587","author":"Stead","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.18632\/oncotarget.2319","article-title":"Regulatory Effects of a Mnk2-eIF4E Feedback Loop during mTORC1 Targeting of Human Medulloblastoma Cells","volume":"5","author":"Eckerdt","year":"2014","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14728222.2019.1571043","article-title":"The MAP Kinase-Interacting Kinases (MNKs) as Targets in Oncology","volume":"23","author":"Xie","year":"2019","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI85183","article-title":"Cotargeting MNK and MEK Kinases Induces the Regression of NF1-Mutant Cancers","volume":"126","author":"Lock","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 Loss Amplifies Ras-Driven Transcription and Confers Sensitivity to BRD4-Based Therapies","volume":"514","author":"Beert","year":"2014","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-24-2807","article-title":"Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Li, W., Hu, C., Zhang, X., Wang, B., Li, Z., Ling, M., Sun, S., Guo, C., Li, D., and Liu, S. (2021). SUZ12 Loss Amplifies the Ras\/ERK Pathway by Activating Adenylate Cyclase 1 in NF1-Associated Neurofibromas. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.738300"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41388-024-03000-9","article-title":"P53 Modulates Kinase Inhibitor Resistance and Lineage Plasticity in NF1-Related MPNSTs","volume":"43","author":"Grit","year":"2024","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gu, Y., Wei, C., Chung, M., Li, H., Guo, Z., Long, M., Li, Y., Wang, W., Aimaier, R., and Li, Q. (2022). Concurrent Inhibition of FAK\/SRC and MEK Overcomes MEK Inhibitor Resistance in Neurofibromatosis Type I Related Malignant Peripheral Nerve Sheath Tumors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.910505"},{"key":"ref_45","unstructured":"Yang, Y., Guo, J., Gurunathan, S., Schechter, S., and Field, J. (2026). TEAD Inhibitors Re-Sensitize Drug-Resistant NF1 MPNST Cells to MEK Inhibitors. MicroPubl. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-25-2887","article-title":"SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)","volume":"32","author":"Kim","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Schulte, A., Ewald, F., Spyra, M., Smit, D.J., Jiang, W., Salamon, J., J\u00fccker, M., and Mautner, V.-F. (2020). Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but Not in a Xenograft Mouse Model In Vivo. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041548"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ji, K., Callaghan, J.F., Ridella, T.J., and Mattingly, R.R. (2026). Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells. Cells, 15.","DOI":"10.3390\/cells15050434"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","article-title":"BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I\/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-Mutant Melanoma","volume":"28","author":"Mehnert","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective Autophagy Elicited by RAF\u2192MEK\u2192ERK Inhibition Suggests a Treatment Strategy for RAS-Driven Cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and Autophagy Inhibition as a Treatment Approach for Pancreatic Cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2012.11.007","article-title":"Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models","volume":"23","author":"Corcoran","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1172\/JCI35437","article-title":"Treatment of B-RAF Mutant Human Tumor Cells with a MEK Inhibitor Requires Bim and Is Enhanced by a BH3 Mimetic","volume":"118","author":"Cragg","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3892\/ijo.2012.1751","article-title":"NF1 Deficiency Causes Bcl-xL Upregulation in Schwann Cells Derived from Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors","volume":"42","author":"Park","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10495-016-1230-9","article-title":"Sec6\/8 Regulates Bcl-2 and Mcl-1, but Not Bcl-Xl, in Malignant Peripheral Nerve Sheath Tumor Cells","volume":"21","author":"Tanaka","year":"2016","journal-title":"Apoptosis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-24-1454","article-title":"Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e154513","DOI":"10.1172\/jci.insight.154513","article-title":"Multiple Nf1 Schwann Cell Populations Reprogram the Plexiform Neurofibroma Tumor Microenvironment","volume":"7","author":"Kershner","year":"2022","journal-title":"JCI Insight"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/s41388-018-0600-x","article-title":"STAT3 Inhibition Reduces Macrophage Number and Tumor Growth in Neurofibroma","volume":"38","author":"Fletcher","year":"2019","journal-title":"Oncogene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2506823122","DOI":"10.1073\/pnas.2506823122","article-title":"A Transcriptomic, Proteomic, and Functional Genetic Atlas Dissects Neurofibromin Function in the Peripheral Nervous System","volume":"122","author":"Vasudevan","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"V600E BRAF Is Associated with Disabled Feedback Inhibition of RAF\u2013MEK Signaling and Elevated Transcriptional Output of the Pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gu, Y., Wang, W., Li, Y., Li, H., Guo, Z., Wei, C., Long, M., Chung, M., Aimaier, R., and Li, Q. (2022). Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.903177"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"638","DOI":"10.18632\/oncotarget.28650","article-title":"Linking FOXM1 and PD-L1 to CDK4\/6-MEK Targeted Therapy Resistance in Malignant Peripheral Nerve Sheath Tumors","volume":"15","author":"Lingo","year":"2024","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ji, K., and Schwenkel, G.J. (2025). Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. Cells, 14.","DOI":"10.3390\/cells14161276"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ji, K., Schwenkel, G.J., Mattingly, R.R., Sundararaghavan, H.G., Zhang, Z.G., and Chopp, M. (2024). A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. Cancers, 16.","DOI":"10.3390\/cancers16142498"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Errico, A., Stocco, A., Riccardi, V.M., Gambalunga, A., Bassetto, F., Grigatti, M., Ferlosio, A., Tadini, G., Garozzo, D., and Ferraresi, S. (2021). Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling. Cancers, 13.","DOI":"10.3390\/cancers13102329"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ji, K., Shi, C., Zhang, J., and Mattingly, R.R. (2026). Mechanical Stiffening Promotes Growth, Invasion-Associated Phenotypes, and Reduced Selumetinib Sensitivity in 3D Plexiform Neurofibroma Cultures. Cells, 15.","DOI":"10.64898\/2026.01.26.701794"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-024-04711-5","article-title":"Precision Oncology in Neurofibromatosis Type 1: Quantification of Differential Sensitivity to Selumetinib in Plexiform Neurofibromas Using Single-Cell RNA Sequencing","volume":"169","author":"Bhandarkar","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1541-7786.MCR-18-1332","article-title":"Intrinsic Resistance to MEK Inhibition through BET Protein\u2013Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer","volume":"17","author":"Kurimchak","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","article-title":"Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-Cell Immunity","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2021.12.009","article-title":"MEK Inhibition Overcomes Chemoimmunotherapy Resistance by Inducing CXCL10 in Cancer Cells","volume":"40","author":"Limagne","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts with Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hung, P.-Y., Moerland, J.A., Leal, A.S., Aleiwi, B., Ellsworth, E., Clapp, D.W., Staedtke, V., Bai, R., and Liby, K.T. (2025). The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model. Cancers, 17.","DOI":"10.3390\/cancers17121920"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., and Mangino, G. (2020). Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12102801"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Vidal-Cruchez, O., Nicolini, V.J., Rete, T., Jacquet, K., Rezzonico, R., Lacoux, C., Domdom, M.-A., Rom\u00e9o, B., Roux, J., and Hubstenberger, A. (2023). KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution. Cancers, 15.","DOI":"10.3390\/cancers15123078"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Alaggio, R., Turrini, R., Boldrin, D., Merlo, A., Gambini, C., Ferrari, A., Dall\u2019Igna, P., Coffin, C.M., Martines, A., and Bonaldi, L. (2013). Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080456"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2018.04.230","article-title":"Trametinib Downregulates Survivin Expression in RB1-Positive KRAS-Mutant Lung Adenocarcinoma Cells","volume":"501","author":"Sumi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_78","first-page":"1220","article-title":"Expression and its clinical significance of cell-cycle dependent kinase 1 in malignant peripheral nerve sheath tumors","volume":"38","author":"Liu","year":"2024","journal-title":"Chin. J. Reparative Reconstr. Surg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13103","DOI":"10.1073\/pnas.240390697","article-title":"Regulation of Apoptosis at Cell Division by P34cdc2 Phosphorylation of Survivin","volume":"97","author":"Grossman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e192658","DOI":"10.1172\/jci.insight.192658","article-title":"Tumor Heterogeneity Underlies Clinical Outcome and MEK Inhibitor Response in Somatic NF1-Mutant Glioblastoma","volume":"10","author":"Pan","year":"2025","journal-title":"JCI Insight"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"eabo5442","DOI":"10.1126\/sciadv.abo5442","article-title":"Single-Cell Multiomics Identifies Clinically Relevant Mesenchymal Stem-like Cells and Key Regulators for MPNST Malignancy","volume":"8","author":"Wu","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 Tumor Suppressor Critically Regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00439-021-02296-x","article-title":"Chromosomal Translocations Inactivating CDKN2A Support a Single Path for Malignant Peripheral Nerve Sheath Tumor Initiation","volume":"140","author":"Terribas","year":"2021","journal-title":"Hum. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eadu2906","DOI":"10.1126\/sciadv.adu2906","article-title":"Somatic CRISPR Tumorigenesis and Multiomic Analysis Reveal a Pentose Phosphate Pathway Disruption Vulnerability in MPNSTs","volume":"11","author":"McGivney","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41379-018-0074-y","article-title":"Inferior Survival for Patients with Malignant Peripheral Nerve Sheath Tumors Defined by Aberrant TP53","volume":"31","author":"Kolberg","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_87","unstructured":"(2026, May 16). DailyMed\u2014KOSELUGO-Selumetinib Capsule KOSELUGO- Selumetinib Granule, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7d042c61-f28f-4ab5-ab10-d7558c0d49ff."},{"key":"ref_88","unstructured":"(2026, May 16). Definition of MEK Inhibitor\u2014NCI Dictionary of Cancer Terms\u2014NCI, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/mek-inhibitor."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Busciglio, S., Cannizzaro, I.R., Luberto, A., Taiani, A., Moschella, B., Ambrosini, E., Cesarini, S., Treccani, M., Azzoni, C., and Bottarelli, L. (2025). The Pathogenesis of the Neurofibroma-to-Sarcoma Transition in Neurofibromatosis Type I: From Molecular Profiles to Diagnostic Applications. Cancers, 17.","DOI":"10.3390\/cancers17243955"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A Convergence-Based Framework for Cancer Drug Resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor Adaptation and Resistance to RAF Inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF\/MEK Inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A Framework to Rank Genomic Alterations as Targets for Cancer Precision Medicine: The ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12967-026-07751-9","article-title":"Personalized Medicine Strategy for MPNSTs: Using Precision Oncology on PDOX Models to Inform Tumor Boards","volume":"24","author":"Mazuelas","year":"2026","journal-title":"J. Transl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2950\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:42:21Z","timestamp":1789137741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":96,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182950"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182950","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}